2157 Stock Overview
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics products in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2157 from our risk checks.
Lepu Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.31 |
| 52 Week High | HK$6.99 |
| 52 Week Low | HK$2.63 |
| Beta | -0.10 |
| 1 Month Change | 35.53% |
| 3 Month Change | 60.82% |
| 1 Year Change | -17.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.64% |
Recent News & Updates
Shareholder Returns
| 2157 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 12.5% | -8.2% | -0.7% |
| 1Y | -17.6% | -46.6% | -13.4% |
Return vs Industry: 2157 exceeded the Hong Kong Biotechs industry which returned -46.6% over the past year.
Return vs Market: 2157 underperformed the Hong Kong Market which returned -13.4% over the past year.
Price Volatility
| 2157 volatility | |
|---|---|
| 2157 Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2157's share price has been volatile over the past 3 months.
Volatility Over Time: 2157's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 429 | Ziye Sui | www.lepubiopharma.com |
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics products in China. The company offers HX008, a humanized IgG4 mAb against human PD-1for the treatment of solid tumors and melanoma. It is conducting phase III clinical study of HX008 in combination therapy with irinotecan, and Phase II clinical trials of HX008 for non-small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma.
Lepu Biopharma Co., Ltd. Fundamentals Summary
| 2157 fundamental statistics | |
|---|---|
| Market cap | HK$7.15b |
| Earnings (TTM) | -HK$23.91m |
| Revenue (TTM) | HK$243.82m |
29.3x
P/S Ratio-299.2x
P/E RatioIs 2157 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2157 income statement (TTM) | |
|---|---|
| Revenue | CN¥225.35m |
| Cost of Revenue | CN¥28.28m |
| Gross Profit | CN¥197.08m |
| Other Expenses | CN¥219.17m |
| Earnings | -CN¥22.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 87.45% |
| Net Profit Margin | -9.81% |
| Debt/Equity Ratio | 78.1% |
How did 2157 perform over the long term?
See historical performance and comparison